FDA Authorizes Use of COVID-19 Antibody Therapy for Postexposure Prophylaxis
The Food and Drug Administration (FDA) has authorized the use of REGEN-COV (casirivimab and imdevimab) for postexposure prophylaxis of COVID-19 in individuals (12 years of age and older weighing at…